Advocates of Big Data analytics often cite their craft as the antidote to gut decisions, arguing more rational, data-driven reasoning is now within the reach of businesses. At Johnson & Johnson they are putting the idea to the test, notably by digging into their employment data to support the hiring of fresh college graduates over industry veterans.
The pharmaceutical industry's producers and academic researchers in Japan are actively engaged, despite setbacks experienced by others such as Google, in building a big-data pipeline, this one now including 10 drugmakers and 30 medical institutions.
Quintiles, the world's largest CRO, has reached out to startup Tute Genomics for access to its database of 8.5 billion annotations of genetic variants.
Big Data initiatives such as President Obama's precision medicine program and the United Kingdom's 100,000 Genomes Project risk losing public trust unless they consider the moral and legal implications of their work, a report has warned.
Alexion Pharmaceuticals has turned to Big Data specialist BioXcel for help identifying its next blockbuster rare disease drug. BioXcel is applying its rare disease database to the collaboration, which aims to figure out which indications are most likely to benefit from various therapeutics.
The National Institutes of Health has kicked off its Big Data to Knowledge (BD2K) initiative with an initial $32 million in funding. Harvard, Stanford and other universities received some of the cash to set up Centers of Excellence for Big Data Computing, each of which will tackle a different aspect of turning numbers into biomedical understanding.
When Flatiron Health emerged in 2012 with a mission to improve oncology care, its founder predicted it would either be "a great success or a horrible failure." Now the Big Data startup is reportedly on the cusp of taking a major step towards the better of these two outcomes, with Fortune writing Google's venture capital wing is leading a $100 million financing round.
The features of Berg Pharma's discovery platform read like a bingo card of hyped approaches, with Big Data sitting alongside genomics and artificial intelligence. Berg has tried to push expectations higher still by claiming it can halve drug development time and costs, but to date the claims--like some of the technologies on which they are based--remain unproven.
Falling sales of personal computers have chipped away at one of the cornerstones of Intel's business over the past few years. The chipmaker has responded by diversifying and this week made three such moves, each of which has implications for the life sciences sector.
Last year 18 universities, companies and government agencies founded the National Consortium for Data Science. The consortium has a broad brief but soon established the challenges and potential of Big Data are writ largest in one field--genomics.